FIA
TBPH icon

FNY Investment Advisers’s Theravance Biopharma TBPH Stock Holding History

FNY Investment Advisers’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,654
Closed -$42K – 948
2018
Q4 		$42K Buy
+1,654
New +$44.7K 0.01% 261

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

FNY Investment Advisers's TBPH Position: Q1 2019 in Review

FNY Investment Advisers sold out of Theravance Biopharma (TBPH) in Q1 2019, closing a stake of 1,654 shares — an estimated $42K sold.

FNY Investment Advisers first reported a position in TBPH in Q4 2018 and held it in 1 quarter. The position peaked at $42K in Q4 2018. 104 funds tracked by Wall St. Rank hold TBPH as of Q1 2019.

  • FNY Investment Advisers reported no remaining Theravance Biopharma position as of Q1 2019 after selling out during the quarter.
  • FNY Investment Advisers sold 1,654 Theravance Biopharma shares in Q1 2019, an estimated $42K.
  • FNY Investment Advisers first reported a position in Theravance Biopharma in Q4 2018 and held it in 1 quarter.
  • FNY Investment Advisers's Theravance Biopharma position peaked at $42K in Q4 2018.
  • 104 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2019.

Based on FNY Investment Advisers's 13F filing for Q1 2019, filed 17 Apr 2019.